Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | FABP3 | P05413 | 2/20 | 0.31 |
| ▸ | FABP4 | P15090 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11574451 | 0.84 | GABRA1 (0.46) | GABRA1GABRB1HTTLMNAALDH1A1 | |
| SCHEMBL422198 | 0.84 | TSHR (0.50) | GABRA1GABRB1HTTLMNAALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL5676040 | 0.81 | TSHR (0.47) | GABRA1GABRB1HTTLMNAALDH1A1 | |
| SCHEMBL19832777 | 0.81 | RAPGEF4 (0.32) | GABRA1GABRB1RAPGEF4TSHR | |
| SCHEMBL17025364 | 0.81 | GABRA1 (0.37) | GABRA1GABRB1RAPGEF4TSHR | |
| SCHEMBL8737182 | 0.81 | RAPGEF4 (0.32) | GABRA1GABRB1RAPGEF4TSHR | |
| SCHEMBL17025386 | 0.81 | GABRA1 (0.37) | GABRA1GABRB1RAPGEF4TSHR | |
| SCHEMBL599485 | 0.81 | ALDH1A1 (0.42) | GABRA1SMN1; SMN2HTTLMNAALDH1A1 | |
| SCHEMBL3363012 | 0.81 | LMNA (0.40) | GABRA1SMN1; SMN2NPSR1HTTLMNA | |
| Hydrogen Peroxide SCHEMBL11577393 | 0.79 | GABRA1 (0.48) | GABRA1GABRB1HTTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| EP-3157929-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | ARES TRADING SA (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023191379-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | 재단법인 대구경북첨단의료산업진흥재단 | 2023-10-05 | — | — | WO | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230265110-A1 | Proteasome Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20090192099-A1 | PRODRUGS OF HETEROARYL COMPOUNDS | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20080249097-A1 | PRODRUGS OF HETEROARYL COMPOUNDS | KORONIS PHARMACEUTICALS, INCORPORATION (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-03-20 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070219200-A1 | PRODRUGS OF HETEROARYL COMPOUNDS | KORONOS PHARMACEUTICALS, INCORPORATED (US) | 2007-09-20 | — | — | US | disclosed |
| US-7244732-B2 | Prodrugs of heteroaryl compounds | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | GABRA1 4260/4885GABRB1 3834/4885RAPGEF4 3925/4885 |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | GABRA1 376/4885GABRB1 321/4885RAPGEF4 1671/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | GABRA1 4260/4885GABRB1 3834/4885RAPGEF4 3925/4885 |
| US-20070219200-A1 | PRODRUGS OF HETEROARYL COMPOUNDS | TYMP, PNP, SLC29A1 | GABRA1 3783/4885GABRB1 3280/4885RAPGEF4 1580/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | GABRA1 713/4885GABRB1 993/4885RAPGEF4 2572/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | GABRA1 713/4885GABRB1 993/4885RAPGEF4 2572/4885 |
| US-20080249097-A1 | PRODRUGS OF HETEROARYL COMPOUNDS | TYMP, PNP, SLC29A1 | GABRA1 3783/4885GABRB1 3280/4885RAPGEF4 1580/4885 |
| US-20230265110-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | GABRA1 3786/4885GABRB1 3753/4885RAPGEF4 3077/4885 |
| US-20090192099-A1 | PRODRUGS OF HETEROARYL COMPOUNDS | TYMP, PNP, SLC29A1 | GABRA1 3783/4885GABRB1 3280/4885RAPGEF4 1580/4885 |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | ACE2, ACE, TMPRSS2 | GABRA1 3840/4885GABRB1 3878/4885RAPGEF4 4134/4885 |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | MCL1, BAK1, BCL2A1 | GABRA1 3917/4885GABRB1 3927/4885RAPGEF4 3046/4885 |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | GABRA1 937/4885GABRB1 1235/4885RAPGEF4 2351/4885 |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLRMT, POLR2H | GABRA1 4582/4885GABRB1 4509/4885RAPGEF4 3673/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | GABRA1 2338/4885GABRB1 2808/4885RAPGEF4 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.